The clinical relevance of animal models in Sjogren's syndrome: the interferon signature from mouse to man

被引:25
|
作者
Maria, Naomi I. [1 ]
Vogelsang, Petra [2 ]
Versnel, Marjan A. [1 ]
机构
[1] Erasmus MC, Dept Immunol, NL-3015 CN Rotterdam, Netherlands
[2] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, N-5021 Bergen, Norway
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; NONOBESE DIABETIC MICE; TOLL-LIKE RECEPTORS; PLASMACYTOID DENDRITIC CELLS; DISTINCT TYPE-I; AUTOIMMUNE EXOCRINOPATHY; SALIVARY-GLANDS; GENE-EXPRESSION; NOD MOUSE; TISSUE INFLAMMATION;
D O I
10.1186/s13075-015-0678-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mouse models have been widely used to elucidate the pathogenic mechanisms of human diseases. The advantages of using these models include the ability to study different stages of the disease with particular respect to specific target organs, to focus on the role of specific pathogenic factors and to investigate the effect of possible therapeutic interventions. Sjogren's syndrome (SS) is a systemic autoimmune disease, characterised by lymphocytic infiltrates in the salivary and lacrimal glands. To date, effective therapy is not available and treatment has been mainly symptomatic. Ongoing studies in murine models are aimed at developing more effective and targeted therapies in SS. The heterogeneity of SS will most probably benefit from optimising therapies, tailored to specific subgroups of the disease. In this review, we provide our perspective on the importance of subdividing SS patients according to their interferon signature, and recommend choosing appropriate mouse models for interferon-positive and interferon-negative SS subtypes. Murine models better resembling human-disease phenotypes will be essential in this endeavour.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] The clinical relevance of animal models in Sjögren’s syndrome: the interferon signature from mouse to man
    Naomi I Maria
    Petra Vogelsang
    Marjan A Versnel
    Arthritis Research & Therapy, 17
  • [2] Type I interferon signature in Sjogren's syndrome: pathophysiological and clinical implications
    Marketos, N.
    Cinoku, I.
    Rapti, A.
    Mavragani, C. P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (03) : S185 - S191
  • [3] Mouse Models of Primary Sjogren's Syndrome
    Park, Young-Seok
    Gauna, Adrienne E.
    Cha, Seunghee
    CURRENT PHARMACEUTICAL DESIGN, 2015, 21 (18) : 2350 - 2364
  • [4] Animal models of Sjogren's syndrome: an update
    Xiao, F.
    Han, M.
    Wang, X.
    Gong, X.
    Huang, E.
    Zhu, Z.
    Zhao, F.
    Zhao, Y.
    Jiang, Q.
    Lu, L.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2019, 37 (03) : S209 - S216
  • [5] Lessons from Animal Models in Sjogren's Syndrome
    Mieliauskaite, Diana
    Kontenis, Vilius
    Siaurys, Almantas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (16)
  • [6] Recent Advances in Mouse Models of Sjogren's Syndrome
    Gao, Yunzhen
    Chen, Yan
    Zhang, Zhongjian
    Yu, Xinhua
    Zheng, Junfeng
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [7] Type I IFN signature in primary Sjogren's syndrome patients
    Brkic, Zana
    Versnel, Marjan A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (04) : 457 - 467
  • [8] Childhood Sjogren syndrome: insights from adults and animal models
    Lieberman, Scott M.
    CURRENT OPINION IN RHEUMATOLOGY, 2013, 25 (05) : 651 - 657
  • [9] Activation of the type I interferon pathway in primary Sjogren's syndrome
    Mavragani, Clio P.
    Crow, Mary K.
    JOURNAL OF AUTOIMMUNITY, 2010, 35 (03) : 225 - 231
  • [10] Animal models of interferon signature positive lupus
    Zhuang, Haoyang
    Szeto, Christopher
    Han, Shuhong
    Yang, Lijun
    Reeves, Westley H.
    FRONTIERS IN IMMUNOLOGY, 2015, 6